Literature DB >> 11168942

HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration.

R J Faull1, J M Stanley, S Fraser, D A Power, D I Leavesley.   

Abstract

BACKGROUND: The mesothelial cell monolayer lining the peritoneal membrane needs constant repair in response to peritonitis and to the toxicity of peritoneal dialysate. In many continuous ambulatory peritoneal dialysis (CAPD) patients, the repair process progressively fails, and membrane dysfunction and fibrosis occur. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has an important role in wound repair and is also fibrogenic, and thus may be involved in these processes in the peritoneal cavity.
METHODS: The presence of HB-EGF, its receptors, and its associated proteins was determined in peritoneal membrane biopsies, cultured human peritoneal mesothelial cells (HPMCs), and peritoneal macrophages from CAPD patients by reverse transcription-polymerase chain reaction, flow cytometry, and immunofluorescence immunocytochemistry with confocal microscopy. HB-EGF effects on HPMC adhesion were measured by a static adhesion assay, on integrin expression by flow cytometry, and on migration by wound healing and chemotaxis assays.
RESULTS: HB-EGF, its receptors HER-1 and HER-4, and the associated proteins CD9, CD44, and integrin alpha(3)beta(1) were expressed by HPMCs and peritoneal macrophages. HB-EGF colocalized with HER-1 and HER-4 in HPMCs and induced their adhesion to collagen type I, expression of beta 1 integrins, and migration.
CONCLUSIONS: HB-EGF is produced by cells in the peritoneal cavity of CAPD patients and has functional effects on HPMCs that would facilitate repair of the mesothelial layer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168942     DOI: 10.1046/j.1523-1755.2001.059002614.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release.

Authors:  Robin N Prince; Eric R Schreiter; Peng Zou; H Steven Wiley; Alice Y Ting; Richard T Lee; Douglas A Lauffenburger
Journal:  J Cell Sci       Date:  2010-06-08       Impact factor: 5.285

2.  Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model.

Authors:  Zhenyuan Li; Hao Yan; Jiangzi Yuan; Liou Cao; Aiwu Lin; Huili Dai; Zhaohui Ni; Jiaqi Qian; Wei Fang
Journal:  Clin Exp Nephrol       Date:  2017-07-14       Impact factor: 2.801

3.  Reduction of peritoneal adhesions by sustained and local administration of epidermal growth factor.

Authors:  S Uguralp; M Akin; A Bay Karabulut; B Harma; Aysel Kiziltay; T R Kiran; N Hasirci
Journal:  Pediatr Surg Int       Date:  2007-11-06       Impact factor: 1.827

4.  Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.

Authors:  Lei Zhang; David Shimizu; Jeffrey L Killeen; Stacey A Honda; Di Lu; Alexander Stanoyevitch; Fritz Lin; Beverly Wang; Edwin S Monuki; Michele Carbone
Journal:  Hum Pathol       Date:  2016-03-11       Impact factor: 3.466

5.  Heparin-binding epidermal growth factor-like growth factor protects mesenchymal stem cells.

Authors:  Daniel J Watkins; Yu Zhou; Chun-Liang Chen; Amanda Darbyshire; Gail E Besner
Journal:  J Surg Res       Date:  2012-05-23       Impact factor: 2.192

Review 6.  The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis.

Authors:  Li Wang; Shougang Zhuang
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

7.  Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.

Authors:  Li Wang; Na Liu; Chongxiang Xiong; Liuqing Xu; Yingfeng Shi; Andong Qiu; Xiujuan Zang; Haiping Mao; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-12-17       Impact factor: 10.121

8.  HB-EGF augments the ability of mesenchymal stem cells to attenuate intestinal injury.

Authors:  Daniel J Watkins; Yu Zhou; Mika A B Matthews; Li Chen; Gail E Besner
Journal:  J Pediatr Surg       Date:  2014-01-31       Impact factor: 2.545

9.  Synergistic effects of HB-EGF and mesenchymal stem cells in a murine model of intestinal ischemia/reperfusion injury.

Authors:  Daniel J Watkins; Jixin Yang; Mika A B Matthews; Gail E Besner
Journal:  J Pediatr Surg       Date:  2013-06       Impact factor: 2.545

10.  Heparin-binding epidermal growth factor-like growth factor gene disruption is associated with delayed intestinal restitution, impaired angiogenesis, and poor survival after intestinal ischemia in mice.

Authors:  Osama N El-Assal; Heather Paddock; Alejandro Marquez; Gail E Besner
Journal:  J Pediatr Surg       Date:  2008-06       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.